# OnCo record gvhd-belumosudil-axatilimab-ibrutinib (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "gvhd-belumosudil-axatilimab-ibrutinib" ;
  schema:name "After ruxolitinib: belumosudil, axatilimab and ibrutinib in chronic GvHD"@en ;
  schema:alternateName "Rezurock"@en, "Niktimvo"@en, "ROCKstar"@en, "AGAVE-201"@en, "iNTEGRATE"@en, "ROCK2 inhibitor"@en, "CSF1R blockade in GvHD"@en ;
  schema:description "Three more drugs are licensed for chronic GvHD that has not responded to earlier treatment. Their response rates look high, between half and three quarters, but they come from trials with no comparison group. Ibrutinib is the cautionary case: it looked good in a single-arm study and then did not beat prednisone alone when tested against placebo."@en ;
  schema:url <https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Belumosudil> ;
  schema:citation <https://doi.org/10.1182/blood.2021012021>, <https://doi.org/10.1056/NEJMoa2401537>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214783>, <https://doi.org/10.1182/blood-2017-07-793786>, <https://doi.org/10.1200/JCO.22.00509> ;
  onco:status "approved" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "evidence:moderate", "gvhd", "treatment" ;
  onco:related <https://onco.cc/technologies/gvhd-chronic-overview/>, <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/>, <https://onco.cc/technologies/gvhd-photopheresis/>, <https://onco.cc/technologies/gvhd-nih-consensus-criteria/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/belumosudil/>, <https://onco.cc/drugs/ibrutinib/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .